Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass

Blood

Volumn 101, Issue 11, 2003, Pages 4355-4362

  Chandler, Wayne L ^a   Velan, Tomas ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBRINOPEPTIDE A; HEPARIN; PROTAMINE; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODILUTION; HUMAN; IN VIVO STUDY; MALE; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STERNOTOMY; TRANSFUSION; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; COMPUTER SIMULATION; KINETICS; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; COMPUTER SIMULATION; FIBRIN; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MYOCARDIAL REPERFUSION; THROMBIN;

EID: 0037804799     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2400     Document Type: Article

References (32)

1. Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest. 1985;76:826-836.
2. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988;59:101-106.
3. Nossel HL, Yudelman I, Canfield RE, et al. Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974;54:43-53.
4. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost. 1999;82:673-683.
5. Cawthern KM, van't Veer C, Lock JB, et al. Blood coagulation in hemophilia A and hemophilia C. Blood. 1998;91:4581-4592.
6. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood. 1999;94:2169-2178.
7. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100:148-152.
8. Chandler WL, Alessi MC, Aillaud MF, et al. Clearance of TPA and TPA/PAI-1 complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.
9. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis. 2000;30:204-218.
10. Chandler WL, Velan T. ACM4WB-an advanced whole body circulatory model. In: Anderson JG, Katzper M, eds. Simulation in the Health and Medical Sciences 2001. San Diego, CA: Soc Comp Simul International: 2001:91-96.
11. Crookston KP, Marsh CL, Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator dunng orthotopic liver transplantation. Blood Coag Fibrinolysis. 2000;11:79-88.
12. Hunt BJ, Parratt RN, Segal HC, et al. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg. 1998;65:712-718.
13. Despotis GJ, Avidan MS, Hogue CWJ. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72:S1821-S1831.
14. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
15. Bos R, Laterveer-Vreeswijk GH, Lockwood D, Szewczyk K, Nieuwenhuizen W. A new enzyme immunoassay for soluble fibrin in plasma with a high discriminating power for thrombotic disorders. Thromb Haemost. 1999;81:54-59.
16. McCarron BI, Marder VJ, Francis CW. Reactivity of soluble fibdn assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Thromb Haemost. 1999;82:1722-1729.
17. Gram J, Jespersen J. Improved assay of antithrombin-III. Effects of certain additives on thrombin and chromogenic peptide substrates. Clin Chem. 1985;31:1683-1688.
18. Mulloy B, Gray E, Barrowcliffe TW. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost. 2000;84:1052-1056.
19. Clauss A. Gerinnungsphysiologische Schnellmethode zu Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-245.
20. Amiral J, Walenga JM, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemost. 1984;10:228-242.
21. Shifman M, Pizzo S. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem. 1982;257:3243-3248.
22. Leonard B, Bies R, Carlson T, Reeve EB. Further studies of the turnover of dog antithrombin III: study of 131 I-labelled antithrombin protease complexes. Thromb Res. 1983;30:165-177.
23. Despotis GJ, Joist JH, Hogue CWJ, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996; 76:902-908.
24. De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2002;123:951-958.
25. Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg. 2002;123:742-755.
26. Aldea GS, O'Gara P, Shapira OM, et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg. 1998;65:425-433.
27. Despotis GJ, Joist JH, Hogue CWJ, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46-54.
28. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth. 1999;13(suppl 1):18-29.
29. Boyle EMJ, Morgan EN, Kovacich JC, Canty TGJ, Verrier ED. Microvascular responses to cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1999;13(suppl 1):30-35.
30. Boyle EMJ, Pohlman TH, Cornejo CJ, Verrier ED. Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion. Ann Thorac Surg. 1996;62: 1868-1875.
31. Boyle EMJ, Verrier ED, Spiess BD. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg. 1996;62: 1549-1557.
32. Rosenberg RD. Vascular-bed-specific hemostasis and hypercoagulable states: clinical utility of activation peptide assays in predicting thrombotic events in different clinical populations. Thromb Haemost. 2001;86:41-50.